Literature DB >> 11283077

Evaluation of mycobacteria growth indicator tube for direct and indirect drug susceptibility testing of Mycobacterium tuberculosis from respiratory specimens in a Siberian prison hospital.

V Goloubeva1, M Lecocq, P Lassowsky, F Matthys, F Portaels, I Bastian.   

Abstract

The manual Mycobacteria Growth Indicator Tube (MGIT) method was evaluated for performing direct and indirect drug susceptibility testing (DST) of Mycobacterium tuberculosis for isoniazid and rifampin on 101 strongly smear-positive sputum specimens in a Siberian prison hospital. Using the indirect method of proportion (MOP) as the "gold standard," the accuracies of isoniazid and rifampin susceptibility testing by the direct MGIT system were 97.0 and 94.1%, respectively. The accuracy of the indirect MGIT system was 98.0% for both drugs. The turnaround times from specimen processing to reporting of the DST results ranged between 4 and 23 (mean, 9.2) days by the direct MGIT method, 9 and 30 (mean, 15.3) days by the indirect MGIT method, and 26 and 101 (mean, 59.6) days by the indirect MOP. MGIT appears to be a reliable, rapid, and convenient method for performing direct and indirect DSTs in low-resource settings, but further studies are required to refine the direct DST protocol. Cost is the only factor prohibiting widespread implementation of MGIT.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11283077      PMCID: PMC87960          DOI: 10.1128/JCM.39.4.1501-1505.2001

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  22 in total

1.  Evaluation of the BBL MGIT (Mycobacterial growth indicator tube) AST SIRE system for antimycobacterial susceptibility testing of Mycobacterium tuberculosis to 4 primary antituberculous drugs.

Authors:  J S Bergmann; G Fish; G L Woods
Journal:  Arch Pathol Lab Med       Date:  2000-01       Impact factor: 5.534

2.  Inadequacy of the current WHO re-treatment regimen in a central Siberian prison: treatment failure and MDR-TB.

Authors:  M E Kimerling; H Kluge; N Vezhnina; T Iacovazzi; T Demeulenaere; F Portaels; F Matthys
Journal:  Int J Tuberc Lung Dis       Date:  1999-05       Impact factor: 2.373

3.  Rapid, low-technology MIC determination with clinical Mycobacterium tuberculosis isolates by using the microplate Alamar Blue assay.

Authors:  S G Franzblau; R S Witzig; J C McLaughlin; P Torres; G Madico; A Hernandez; M T Degnan; M B Cook; V K Quenzer; R M Ferguson; R H Gilman
Journal:  J Clin Microbiol       Date:  1998-02       Impact factor: 5.948

4.  Mycobacterial growth indicator tube for susceptibility testing of Mycobacterium tuberculosis to isoniazid and rifampin.

Authors:  J S Bergmann; G L Woods
Journal:  Diagn Microbiol Infect Dis       Date:  1997-07       Impact factor: 2.803

5.  Rapid, efficient detection and drug susceptibility testing of Mycobacterium tuberculosis in sputum by microscopic observation of broth cultures. The Tuberculosis Working Group in Peru.

Authors:  L Caviedes; T S Lee; R H Gilman; P Sheen; E Spellman; E H Lee; D E Berg; S Montenegro-James
Journal:  J Clin Microbiol       Date:  2000-03       Impact factor: 5.948

6.  Two liquid medium systems, mycobacteria growth indicator tube and MB redox tube, for Mycobacterium tuberculosis isolation from sputum specimens.

Authors:  L Heifets; T Linder; T Sanchez; D Spencer; J Brennan
Journal:  J Clin Microbiol       Date:  2000-03       Impact factor: 5.948

7.  Evaluation of Mycobacteria Growth Indicator Tube (MGIT) for drug susceptibility testing of Mycobacterium tuberculosis.

Authors:  J C Palomino; H Traore; K Fissette; F Portaels
Journal:  Int J Tuberc Lung Dis       Date:  1999-04       Impact factor: 2.373

8.  Direct antimicrobial drug susceptibility testing of Mycobacterium tuberculosis by the radiometric method.

Authors:  J P Libonati; C E Stager; J R Davis; S H Siddiqi
Journal:  Diagn Microbiol Infect Dis       Date:  1988-05       Impact factor: 2.803

9.  Evaluation of mycobacteria growth indicator tubes for susceptibility testing of Mycobacterium tuberculosis to isoniazid and rifampin.

Authors:  B S Reisner; A M Gatson; G L Woods
Journal:  Diagn Microbiol Infect Dis       Date:  1995-08       Impact factor: 2.803

10.  Multicenter evaluation of the mycobacteria growth indicator tube for testing susceptibility of Mycobacterium tuberculosis to first-line drugs.

Authors:  S Rüsch-Gerdes; C Domehl; G Nardi; M R Gismondo; H M Welscher; G E Pfyffer
Journal:  J Clin Microbiol       Date:  1999-01       Impact factor: 5.948

View more
  18 in total

1.  Kanamycin susceptibility testing of Mycobacterium tuberculosis using Mycobacterium Growth Indicator Tube and a colorimetric method.

Authors:  I Bastian; L Rigouts; J C Palomino; F Portaels
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

2.  Direct drug susceptibility testing of Mycobacterium tuberculosis for rapid detection of multidrug resistance using the Bactec MGIT 960 system: a multicenter study.

Authors:  Salman Siddiqi; Altaf Ahmed; Sunil Asif; Digamber Behera; Mona Javaid; Jasmine Jani; Arora Jyoti; Radhika Mahatre; Dewanand Mahto; Elvira Richter; Camilla Rodrigues; Potharaju Visalakshi; Sabine Rüsch-Gerdes
Journal:  J Clin Microbiol       Date:  2011-12-07       Impact factor: 5.948

3.  Direct colorimetric assay for rapid detection of rifampin-resistant Mycobacterium tuberculosis.

Authors:  Getahun Abate; Abraham Aseffa; Alemayehu Selassie; Solomon Goshu; Bekele Fekade; Dawit WoldeMeskal; Håkan Miörner
Journal:  J Clin Microbiol       Date:  2004-02       Impact factor: 5.948

4.  Does the MGIT 960 system improve the turnaround times for growth detection and susceptibility testing of the Mycobacterium tuberculosis complex?

Authors:  Akos Somoskovi; Anne Clobridge; Susan C Larsen; Oleg Sinyavskiy; Suheyla Surucuoglu; Linda M Parsons; Max Salfinger
Journal:  J Clin Microbiol       Date:  2006-06       Impact factor: 5.948

5.  Evaluation of microscopic observation drug susceptibility assay for detection of multidrug-resistant Mycobacterium tuberculosis.

Authors:  Girum Shiferaw; Yimtubezinash Woldeamanuel; Mekdes Gebeyehu; Feven Girmachew; Daniel Demessie; Eshetu Lemma
Journal:  J Clin Microbiol       Date:  2007-01-24       Impact factor: 5.948

6.  Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of Mycobacterium tuberculosis to classical second-line drugs and newer antimicrobials.

Authors:  Sabine Rüsch-Gerdes; Gaby E Pfyffer; Manuel Casal; Maureen Chadwick; Salman Siddiqi
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948

7.  Rapid and inexpensive detection of multidrug-resistant Mycobacterium tuberculosis with the nitrate reductase assay using liquid medium and direct application to sputum samples.

Authors:  Dissou Affolabi; Mathieu Odoun; N'Dira Sanoussi; Anandi Martin; Juan Carlos Palomino; Luc Kestens; Séverin Anagonou; Françoise Portaels
Journal:  J Clin Microbiol       Date:  2008-08-27       Impact factor: 5.948

8.  Drug susceptibility testing of Mycobacterium tuberculosis by a nitrate reductase assay applied directly on microscopy-positive sputum samples.

Authors:  Humberto R Musa; Marta Ambroggi; Alejandro Souto; K A Kristian Angeby
Journal:  J Clin Microbiol       Date:  2005-07       Impact factor: 5.948

9.  An integrated approach to rapid diagnosis of tuberculosis and multidrug resistance using liquid culture and molecular methods in Russia.

Authors:  Yanina Balabanova; Francis Drobniewski; Vladyslav Nikolayevskyy; Annika Kruuner; Nadezhda Malomanova; Tatyana Simak; Nailya Ilyina; Svetlana Zakharova; Natalya Lebedeva; Heather L Alexander; Rick O'Brien; Hojoon Sohn; Anastasia Shakhmistova; Ivan Fedorin
Journal:  PLoS One       Date:  2009-09-23       Impact factor: 3.240

10.  Possible outbreak of streptomycin-resistant Mycobacterium tuberculosis Beijing in Benin.

Authors:  Dissou Affolabi; Frank Faïhun; N'Dira Sanoussi; Gladys Anyo; Isdore Chola Shamputa; Leen Rigouts; Luc Kestens; Séverin Anagonou; Françoise Portaels
Journal:  Emerg Infect Dis       Date:  2009-07       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.